Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | August 28, 2025 | September 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spero Therapeutics, Inc.
Report date August 28, 2025 · Filed September 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 703,294 |
Reported balance
After 2025-08-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-28 · Sale · Disposed 6,572 · Balance 703,294 F1: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock unit ("RSUs") that were granted to the Reporting Person on August 26, 2021. F2: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock unit ("RSUs") that were granted to the Reporting Person on August 26, 2021.
F2: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2020 Filed Jun 30, 2020 01:21 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionCommon Stock | 8,045 | $5.90 | $47,465.50 |
DisclosureSEC source: 0001209191-20-039352 · doc4.xml · nonDerivative · entry 3 Mahadevia Ankit · CIK 0001720974 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares). F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| June 22, 2020 Filed Jun 30, 2020 01:21 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,613 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-20-039352 · doc4.xml · derivative · entry 9 Mahadevia Ankit · CIK 0001720974 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,196 Underlying: Common Stock · 2,613 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 22, 2020 Filed Jun 30, 2020 01:21 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 2,613 | $14.30 | $37,364.85 |
DisclosureSEC source: 0001209191-20-039352 · doc4.xml · nonDerivative · entry 2 Mahadevia Ankit · CIK 0001720974 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,817 F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares). F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| June 22, 2020 Filed Jun 30, 2020 01:21 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionCommon Stock | 2,613 | $5.90 | $15,416.70 |
DisclosureSEC source: 0001209191-20-039352 · doc4.xml · nonDerivative · entry 1 Mahadevia Ankit · CIK 0001720974 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares). F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| February 03, 2020 Filed Feb 3, 2020 22:32 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $9.34 | $0.00 |
DisclosureSEC source: 0000899243-20-002617 · doc4.xml · derivative · entry 1 Mahadevia Ankit · CIK 0001720974 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2030-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:12 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0000899243-19-000175 · doc4.xml · derivative · entry 1 Mahadevia Ankit · CIK 0001720974 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · derivative · entry 12 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,888 Underlying: Common Stock · 1,600 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option were fully vested as of July 6, 2017. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 200 | $17.92 | $3,584.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 10 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,817 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 200 | $17.90 | $3,580.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 9 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,017 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 100 | $17.71 | $1,770.50 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 8 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,217 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 100 | $17.62 | $1,762.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 7 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,317 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 400 | $17.58 | $7,032.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 6 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,417 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 100 | $17.55 | $1,754.50 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 5 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,817 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 500 | $17.50 | $8,750.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 4 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,917 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionCommon Stock | 1,600 | $5.90 | $9,440.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 3 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,076 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · derivative · entry 11 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,488 Underlying: Common Stock · 3,076 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option were fully vested as of July 6, 2017. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 3,076 | $17.62 | $54,203.73 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 2 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,817 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionCommon Stock | 3,076 | $5.90 | $18,148.40 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 1 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 125,079 | $0.00 Strike: $11.63 | $0.00 |
DisclosureSEC source: 0000899243-17-028846 · doc4.xml · derivative · entry 1 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,079 Underlying: Common Stock · 125,079 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.